20.85
+3.47%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ScinoPharm Taiwan
Its shares trade on Taiwan Stock Exchange under the ticker 1789.TW. It has been listed since 29 October 2010. In the fiscal year to 31 December 2025, it reported revenue of TWD 3.16bn and net income of TWD 137.0m. At that date it held total assets of TWD 11.86bn and shareholders' equity of TWD 10.52bn.
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Oct 2010
- Website
- scinopharm.com.tw ↗
Leadership
Pay as last reported
- Mr. Chih-Hsien LoChairman of the Board, General Chief Strategy Officer, since 2010
- Ms. Li-An LuChief Executive Officer, General Manager
- Mr. John TsaiGeneral Manager-SPC
- Ms. Li-Chiao ChangChief Scientific Officer, Deputy General Manager-R&D, since 2018
- Ms. Katy ChengDeputy General Manager-Quality Management
- Mr. Ling-Hsiao LienDeputy General Manager-Marketing & Sales and Operations
- Yung-Chih TsaiHead of Finance, Corporate Governance Officer
- Yao-Hui WangHead of Accounting
- Mr. Chin-Yuan ChengDirector
- Mr. Jia-Horng GuoDirector
- Mr. Po-Ming HouDirector
- Ms. Ming-Chuan HsiehDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 99
- Social
- 99
- Governance
- 43
- Direct emissions (scope 1)
- 4,292.54 t
- Energy emissions (scope 2)
- 17,067.97 t
- Women in the workforce
- 31.0757%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ScinoPharm Taiwan Ltd is a leading pharmaceutical company with a strong reputation in the industry. It has an extensive knowledge base and expertise in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs).
- The company has a state-of-the-art infrastructure and facilities that adhere to international quality standards. This enables them to efficiently produce large quantities of APIs, ensuring consistent supply to their customers.
- ScinoPharm has a diverse portfolio of products, catering to various therapeutic areas. This allows them to serve a wide range of customers and capture market opportunities across different segments.
Weaknesses
- One of the main weaknesses of ScinoPharm Taiwan Ltd is its dependence on a limited number of key customers. Any significant loss of these key customers could have a significant impact on the company's revenue.
- The company also faces regulatory and compliance challenges, especially when it comes to ensuring adherence to international quality standards. Any failure to meet these standards could result in legal issues and damage to the company's reputation.
- ScinoPharm may also struggle with competition from larger multinational pharmaceutical companies that have greater resources and global reach.
Opportunities
- The pharmaceutical industry is experiencing a growing demand for APIs, driven by the increasing prevalence of chronic diseases and the need for innovative treatments. ScinoPharm can capitalize on this opportunity by expanding its product portfolio and exploring new therapeutic areas.
- The company can also leverage advancements in technology to optimize its manufacturing processes and improve efficiency. This can result in cost savings and increased competitiveness.
- Furthermore, ScinoPharm can consider strategic partnerships and collaborations with other pharmaceutical companies to enhance its market presence and explore new markets.
Threats
- One of the major threats faced by ScinoPharm Taiwan Ltd is the increasing competition in the pharmaceutical industry. The presence of well-established players and new entrants can pose challenges to the company's market share and growth.
- External factors such as changes in government regulations and policies, economic downturns, and currency fluctuations can also impact ScinoPharm's operations and financial performance.
- In addition, the company may face risks related to intellectual property infringement and counterfeit products, which can damage its brand image and revenue stream.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.